It may also be important to understand the possibility of high ApoER2 expression and unintended SeP overaccumulation as a drug action, as PCSK9 inhibitors are already used as clinical agents for hyperlipidemia [47]; the relationship between SeP excess and disease may also have implications for drug development. Here, LRP8 is linked to hyperlipidemia.